Fintech

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

Globenewswire·March 30, 2026 at 11:15 AM

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement...

Original Source

Globenewswire — www.globenewswire.com

Related in Fintech

NY Fed: Mobile Sports Betting Increases Credit Delinquency
PYMNTS
Labor Department Eases 401(k) Alternative Investment Access
PYMNTS
US rule may open trillions in 401(k) to crypto
CoinDesk
Businesses Adapt AI Budgeting to Usage-Based Pricing
PYMNTS

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

NY Fed: Mobile Sports Betting Increases Credit Delinquency

Labor Department Eases 401(k) Alternative Investment Access

US rule may open trillions in 401(k) to crypto

Businesses Adapt AI Budgeting to Usage-Based Pricing